Navigation Links
Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis

EVRY, France, April 04, 2007 /PRNewswire/ -- Novagali Pharma, an emerging ophthalmic pharmaceutical company specialized in ophthalmology, announces today positive results from the Phase III clinical study of Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC). In this orphan disease, it was shown that both symptoms and signs of disease improved in patients receiving Vekacia(R). Furthermore, the tolerability to Vekacia(R) was excellent.

VKC is a severe form of chronic allergic conjunctivitis characterized by ocular discomfort, pain, itching and intense photophobia, which severely debilitates the patients. This rare disease affects mostly children and young adults living in warm climates worldwide. In March 2006, Novagali received European Medicines Agency (EMEA) orphan drug designation for Vekacia(R) in the treatment of VKC.

The study was conducted by key experts and opinion leaders in the field of ocular allergy throughout Europe and Mediterranean area and lead by Pr David Ben Ezra, Hadassah Hebrew University Hospital, Jerusalem, who first reported on the use and potential efficacy of Cyclosporine A for the treatment of VKC.

Vekacia(R) is a topical Cyclosporine A cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy. This proprietary ophthalmic emulsion of Cyclosporine A will be the first therapeutic product dedicated to treatment of such a severe ocular condition.

"We achieved a major corporate milestone completing our first phase III clinical trial" declares Jerome Martinez, President & CEO of Novagali, "I am very enthusiastic about the confirmation of the high potential of Novasorb(R) cationic emulsion technology through the development of Vekacia(R) and its successful use in VKC. It is very encouraging for the other ongoing projects".

"It is a great satisfaction to b
'"/>




Page: 1 2

Related medicine technology :

1. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:9/3/2015)... Sept. 3, 2015 OticPharma, Ltd., a privately ... for ear, nose, and throat (ENT) disorders, today announced ... complex to be the location of its new U.S. ... of September and will have office locations in both ... OticPharma, Inc. 19900 MacArthur Blvd., Suite 550 ...
(Date:9/2/2015)... , Sept. 2, 2015 This report ... the current and future prospects of the global ... health and assists medical practitioners in deciding the ... progression during treatment. Multi-parameter patient monitoring is effective ... disease. Geriatric population is observed to be at ...
(Date:9/2/2015)... , Sept. 2, 2015 About ... is used to treat an unruptured and ruptured ... wall). The treatment is either known as an ... the endovascular coil blocks the blood flow in ... performed under general anaesthesia by an interventional neuroradiologist ...
Breaking Medicine Technology:OticPharma Establishes U.S. Headquarters in Orange County, California 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... Sept. 19 Immtech Pharmaceuticals,Inc. (Amex: ... Food and Drug Administration,(FDA) has granted Orphan ... African Trypanosomiasis (HAT), also known as African,sleeping ... numerous,financial and regulatory benefits during pafuramidine,s development,including ...
... Both Cultures and Spores of the ... CHICAGO, Sept. 19 Targanta Therapeutics Corporation,today released ... activity of its,lead antibiotic drug candidate, oritavancin, to ... are being presented today,at the 47th Annual Interscience ...
Cached Medicine Technology:US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 2US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 3Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria 2Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria 3
(Date:9/3/2015)... ... 2015 , ... Hunters Creek Retrievers is again honored to salute ... Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 Kisses from a ... and Christmas with an extra big smile. , This adorable trained Lab Pup ...
(Date:9/3/2015)... ... ... an unavoidable result of incision or injury to the skin. Unsightly as it may be, ... of a scar is dependent on many factors – the size and depth of the ... near invisibility on their own over a period of months,” says Dr. Jocelyn Lieb ...
(Date:9/3/2015)... ... September 03, 2015 , ... Representatives with State Farm Agent ... anticipated Mississippi Gulf Babypalooza on September 19, 2015. , “We will be providing ... and beyond. We will be discussing setting up college funds, offering information specific ...
(Date:9/3/2015)... ... ... cases of prostate cancer are reported each year, along with 27,540 deaths attributed to the ... While only one man in 10,000 will typically get prostate cancer under age 40, the ... American Cancer Society. , Prostate cancer is the second leading cause of ...
(Date:9/3/2015)... FLORIDA (PRWEB) , ... September 03, 2015 , ... ... of the highest-regarded health professionals out there. His perspective on internal medicine keeps patients ... stay happy and healthy is important regardless of the season, but even more so ...
Breaking Medicine News(10 mins):Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2
... QUINCY, Mass., April 17 The Stop & Shop Supermarket,Company ... of Chang,Farm Brand 12oz packages of Soy Sprouts with a ... of 00 29899 0100., The product is being recalled ... in food such as sprouts,represents a significant danger to public ...
... International Union taking immediate legal steps to,dismiss ... Nurses,Association, WASHINGTON, April 17 The ... to file a motion to,dismiss the temporary ... Association against SEIU President Andy Stern and ...
... Hospitals of America,(PHA) today strongly denounced efforts by ... the farm bill in their continuing effort,to close ... is the latest effort by opponents of hospitals ... bureaucrats and non-physician,corporations and has already drawn strong ...
... first showing the cancer may have an Achilles, heel, report ... drug Gleevec has forced metastatic melanoma into remission for the ... Boston. , The case involves a 79-year-old woman with melanoma ... carried an abnormality in a gene called KIT, so the ...
... Consumer,Watchdog today praised a California state regulator,s ... left uninsured, uninsurable,and often hundreds of thousands of ... were illegally cancelled after they got sick. The,nonprofit ... and retroactive, with no gap in coverage from ...
... The American,Chemistry Council (ACC) today sent a ... to update its review of the safety of ... body of scientific study regarding bisphenol A is ... have,raised concerns about the safety and use of ...
Cached Medicine News:Health News:SEIU to File Motion to Dismiss CNA Restraining Order 2Health News:Physician Hospitals of America Denounces 'Farm Bill' Plan to Sell Out Seniors and Physicians to Pay for Agribusiness Subsidies 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2Health News:Consumer Watchdog Praises CA HMO Regulator's Promise to Reinstate Health Coverage for Wrongfully Cancelled Patients; Cautions That All Health Costs During Gap Must be Covered 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: